2021
Management of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosis
2010
Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver
Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver. American Journal Of Clinical Oncology 2010, 33: 474-480. PMID: 19935383, DOI: 10.1097/coc.0b013e3181b4b065.Peer-Reviewed Original ResearchConceptsHepatic arterial chemoembolizationOcular melanoma metastaticProgression-free survival durationMedian OS durationOverall survivalLactate dehydrogenase levelsMelanoma metastaticRadiologic responseLiver involvementSurvival durationOS durationDehydrogenase levelsResponse rateBaseline lactate dehydrogenase levelsHigher lactate dehydrogenase levelsMedian overall survivalTumor response rateHepatic artery chemoembolizationShorter overall survivalStable diseaseDisease stabilizationProgressive diseaseArterial chemoembolizationMost patientsPartial response
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survival
2008
Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases. Annals Of Surgical Oncology 2008, 15: 2765. PMID: 18636296, PMCID: PMC5901734, DOI: 10.1245/s10434-008-0035-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsEmbolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsLiver RegenerationMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinPortal VeinPrognosisProspective StudiesSurvival RateTreatment OutcomeConceptsPortal vein embolizationColorectal liver metastasesVascular endothelial growth factorLiver metastasesLiver regenerationPreoperative chemotherapyFLR hypertrophyLiver resectionVein embolizationFuture liver remnant volumeFLR volume increaseMajor liver resectionLiver remnant volumeEffect of chemotherapyImpairs liver regenerationEndothelial growth factorConclusionPreoperative chemotherapyConcurrent bevacizumabProspective databaseRight hepatectomyPostoperative outcomesConsecutive patientsRemnant volumeBevacizumabMurine model
2006
Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors
Kobayashi K, Gupta S, Trent JC, Vauthey J, Krishnamurthy S, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, McRae SE, Hicks ME. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors. Cancer 2006, 107: 2833-2841. PMID: 17096432, DOI: 10.1002/cncr.22336.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationGastrointestinal stromal tumorsUse of imatinibOverall survivalOS timeLiver diseaseStromal tumorsTumor responseMetastatic gastrointestinal stromal tumorsExtensive liver involvementMedian OS timeObjective tumor responseMedian PFS timeProgression-free survivalKaplan-Meier methodMajority of patientsDurable tumor responsesExtrahepatic diseaseOS ratesRadiologic responseStable diseaseDisease stabilizationPFS timeExtrahepatic metastasesLiver involvement
2005
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey J, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer 2005, 104: 1590-1602. PMID: 16134179, DOI: 10.1002/cncr.21389.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoid TumorCarcinoma, Islet CellChemoembolization, TherapeuticDisease-Free SurvivalEmbolization, TherapeuticFemaleFollow-Up StudiesHepatic ArteryHumansLiver NeoplasmsMaleMedical RecordsMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival RateConceptsHepatic arterial embolizationProgression-free survivalIslet cell carcinomaMetastatic neuroendocrine tumorsIntact primary tumorOverall survivalCarcinoid tumorsCell carcinomaHigh response rateNeuroendocrine tumorsMultivariate analysisArterial embolizationBone metastasesPrimary tumorMale genderRisk factorsPrognostic variablesResponse rateOnly independent risk factorLonger progression-free survivalPancreatic islet cell carcinomaExtensive liver diseaseOutcomes of patientsIndependent risk factorOnly risk factor